Conference Reports for NATAP

Back

20th APASL Conference of the Asian Pacific Association for the Study of the Liver 2010 March 2010 Beijing, China     Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40KD] (PEGASYS) plus lamivudine or adefovir for 96 weeks results in high rates of HBsAg clearance / seroconversion - (03/31/10)   Identification of a baseline algorithm to select chronic hepatitis B patients for therapy with peginterferon alfa-2a [40KD] (PEGASYS) - (03/31/10)   A pilot study of interferon alpha/peginterferon alfa-2a combined with response-guided short-term nucleoside analog therapy in HBeAg-positive hepatitis B patients - (03/31/10)   A Phase 1b Dose-Ranging Study of 4 Weeks of PEG-Interferon (IFN) Lambda (PEG-rIL-29) in Combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) I - (03/31/10)   Tenofovir 3- Year Efficacy, Safety and Resistance - Treatment in HBeAg Positive and Negative Patients with Chronic Hepatitis B - (03/31/10)   3 Years Efficacy and Safety of Tenofovir in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B - (03/31/10)   Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation - (03/31/10)   The Antiviral Effects and Safety of Entecavir Versus Lamivudine Treatment in Nucleos(t)ide-naïve HBeAg-negative Korean Chronic Hepatitis B Patients: Week 48 Interim Analysis - (03/31/10)   On-Treatment Decline in Serum HBsAg Levels Predicts Sustained Immune Control 1 Year Post-Treatment and Subsequent HBsAg Clearance in HBeAg-Negative Hepatitis B Virus-Infected Patients Treated with Peginterferon Alfa-2a [40KD] (PEGASYS) - (03/31/10)   On-Treatment Decline in Serum HBsAg Levels Predicts Sustained Immune Control and HBsAg Clearance 6 Months Post-Treatment in HBeAg-Positive Hepatitis B Virus-Infected Patients Treated with Peginterferon Alfa-2a [40KD] (PEGASYS) - (03/31/10)   Sustained Immune Control 1 Year Post-Treatment with Peginterferon Alfa-2a [40KD] (PEGASYS) is Durable up to 5 Years Post-Treatment and is Associated with a High Rate of HBsAg Clearance in HBeAg-Negative Chronic Hepatitis B - (03/31/10)   Large International, Observational Study of Patients with Chronic Hepatitis B Infection Treated with Peginterferon Alfa-2a [40KD] (PEGASYS): the S-Collate Cohort - (03/31/10)   Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single- and Multiple-Dose Administration of BMS-650032, a Novel HCV NS3 Inhibitor, in Subjects with Chronic Genotype 1 HCV Infection - (03/30/10)   BMS-790052 is a First-in-class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study - (03/30/10)